Doctors have nearly a dozen new targeted drugs to treat patients with acute myeloid leukemia, or AML, yet three of four patients still die within five years.
Proteogenomics reveals new target for beating drug resistance in acute myeloid leukemia
- Post author:
- Post published:February 2, 2024
- Post category:uncategorized